ANTIBACTERIAL ACTIVITY OF DL 473, A NEW SEMISYNTHETIC RIFAMYCIN DERIVATIVE

DL 473, a new semisynthetic rifamycin, was 2-10 times more active in vitro than rifampicin (RAMP) against several clinical isolates of Mycobacterium tuberculosis and only slightly less active than RAMP against Gram-positive and Gram-negative bacteria. It showed excellent therapeutic activity in mice...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antibiotics 1981, Vol.34(8), pp.1026-1032
Main Authors: ARIOLI, VITTORIO, BERTI, MARISA, CARNITI, GIULIANA, RANDISI, ELEONORA, ROSSI, ELSA, SCOTTI, ROBERTO
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - pharmacology
Bacteria - drug effects
Bacterial Infections - drug therapy
Dose-Response Relationship, Drug
Isoniazid - therapeutic use
Klebsiella pneumoniae
Mice
Microbial Sensitivity Tests
Mycobacterium tuberculosis
Rifampin - analogs & derivatives
Rifampin - metabolism
Rifampin - pharmacology
Rifampin - therapeutic use
Streptococcus pneumoniae
Streptococcus pyogenes
Tuberculosis - drug therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:DL 473, a new semisynthetic rifamycin, was 2-10 times more active in vitro than rifampicin (RAMP) against several clinical isolates of Mycobacterium tuberculosis and only slightly less active than RAMP against Gram-positive and Gram-negative bacteria. It showed excellent therapeutic activity in mice in experimental infections caused by Staphylococcus aureus, Streptococcus pyogenes group A, Streptococcus pneumoniae and Klebsiella pneumoniae. In the experimental TB infection in the mouse DL 473 was clearly more active than isoniazide and RAMP, two of the most effective antitubercular drugs in current use. The LD50 in the mouse was significantly higher than that of RAMP and the half-life was about 5 times longer than that of RAMP.
ISSN:0021-8820
1881-1469
DOI:10.7164/antibiotics.34.1026